SCHEMBL5741983

SCHEMBL5741983

CC(OS(C)(=O)=O)c1noc(-c2cccc(Cl)c2)n1.CS(=O)(=O)Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.51
GRM5 P41594 4/20 0.49
RAB9A P51151 4/20 0.46
KMT2A Q03164 3/20 0.46
NPC1 O15118 5/20 0.46
MAPT P10636 5/20 0.46
TSHR P16473 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 2/20 0.45
TP53 P04637 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MITF O75030 1/20 0.42
PKM P14618 1/20 0.42
S1PR1 P21453 1/20 0.41
S1PR3 Q99500 1/20 0.41
GPR119 Q8TDV5 1/20 0.39
PPARG P37231 1/20 0.38
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
PLCG2 P16885 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1545485 0.98 KCNH2 (0.53) KCNH2GRM5RAB9AKMT2ANPC1
Methane SCHEMBL5741987 0.97 KCNH2 (0.50) KCNH2GRM5RAB9AKMT2ANPC1
SCHEMBL5741985 0.86 KCNH2 (0.49) KCNH2GRM5RAB9AKMT2ANPC1
SCHEMBL3107768 0.84 RAB9A (0.47) KCNH2GRM5RAB9AKMT2ANPC1
SCHEMBL3107772 0.84 RAB9A (0.47) KCNH2GRM5RAB9AKMT2ANPC1
SCHEMBL1544764 0.79 KCNH2 (0.53) KCNH2GRM5RAB9AKMT2ANPC1
SCHEMBL1544766 0.79 KCNH2 (0.53) KCNH2GRM5RAB9AKMT2ANPC1
SCHEMBL1544487 0.77 MAPT (0.55) KCNH2GRM5RAB9AKMT2ANPC1
SCHEMBL5126441 0.76 RAB9A (0.53) GRM5RAB9AKMT2ANPC1MAPT
SCHEMBL1544494 0.76 MAPT (0.53) KCNH2GRM5RAB9AKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1716152-A2 FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS AstraZeneca AB (SE) 2006-11-02 EP disclosed
WO-2005080397-A2 FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS ASTRAZENECA AB (SE) 2005-09-01 WO disclosed